Concepedia

Author

H. van Dekken

Erasmus University Rotterdam

Also Known As

H Van Dekken, H van Dekken, H. VAN DEKKEN, H. Van Dekken, H. van Dekken, Horman van Dekken

27

Publications

572

Citations

9

H-Index

5

Concepts

All Affiliations

Erasmus University RotterdamErasmus MCSint Franciscus GasthuisIkazia Ziekenhuis
HV

About

H. van Dekken is an author at Erasmus University Rotterdam specializing in surgical oncology, surgery, and gastroenterology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

13

2

Gastroenterology

1

1

13

3

Surgical Oncology

1

1

13

4

Thoracic Surgery

1

1

13

5

Surgery

1

1

13

H. van Dekken

×

9

Publications

546

Citations

9

H-Index

YearCitations

Predictors for Neoplastic Progression in Patients With Barrett's Esophagus: A Prospective Cohort Study

Marjolein Sikkema, Caspar W.N. Looman, Ewout W. Steyerberg,

The American Journal of Gastroenterology

2011

172

Risk Factors for the Development of Esophageal Adenocarcinoma in Barrett's Esophagus

Pieter Jan F. de Jonge, Ewout W. Steyerberg, Ernst J. Kuipers,

The American Journal of Gastroenterology

2006

108

The homeodomain protein CDX2 is an early marker of Barrett’s oesophagus

Leon M.G. Moons, Dorine A. Bax, E.J. Kuipers,

Journal of Clinical Pathology

2004

103

Detection of host cells following sex-mismatched bone marrow transplantation by fluorescent in situ hybridization with a Y-chromosome specific probe.

H. van Dekken, Anton Hagenbeek, J. G. J. Bauman

PubMed

1989

42

Oesophagitis is common in patients with achalasia after pneumatic dilatation

Ivonne Leeuwenburgh, H. van Dekken, Pieter Scholten,

Alimentary Pharmacology & Therapeutics

2006

31

Environmental risk factors in the development of adenocarcinoma of the oesophagus or gastric cardia: a cross‐sectional study in a Dutch cohort

Pieter Jan F. de Jonge, Leonieke M. M. Wolters, Ewout W. Steyerberg,

Alimentary Pharmacology & Therapeutics

2007

29

Proton pump inhibitor therapy in gastro‐oesophageal reflux disease decreases the oesophageal immune response but does not reduce the formation of DNA adducts

Pieter Jan F. de Jonge, Peter D. Siersema, Simone G. van Breda,

Alimentary Pharmacology & Therapeutics

2008

27

Original article: Expression of p53 as predictor for the development of esophageal cancer in achalasia patients

Ivonne Leeuwenburgh, Monique M. Gerrits, Astrid Capello,

Diseases of the Esophagus

2010

21

No survival benefit of extended transthoracic resection over limited transhiatal resection for adenocarcinoma of the mid/distal esophagus and gastric cardia: results of a randomized study.

Jan B.F. Hulscher, Angela G. E. M. de Boer, Johanna W. van Sandick,

Data Archiving and Networked Services (DANS)

2002

13

Page 1